Zheng Zhipeng, Wang Hanying, Jiang Hanliang, Chen Enguo, Zhang Jun, Xie Xinyou
Department of Clinical Laboratory Department of Medical Oncology Department of Respiratory Medicine, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China.
Medicine (Baltimore). 2017 Nov;96(45):e8507. doi: 10.1097/MD.0000000000008507.
Pulmonary epithelioid hemangioendothelioma (P-EHE) is a rare tumor, with no established standard treatment. Overexpression of vascular endothelial growth factor receptor 2 (VEGFR-2) has been reported in some P-EHE patients. Apatinib, a new small molecule tyrosine kinase inhibitor that specifically targets VEGFR-2, has therapeutic benefits in some advanced tumors. However, its efficacy in P-EHE cases has not been reported.
Herein, we presented a 44-year-old man with recurrent hemoptysis for approximately 9 years.
After hospitalization, relevant examinations were conducted. The disease was subsequently diagnosed as P-EHE.
The patient underwent pulmonary lobectomy, but subsequently developed multiple metastases. Within the tumor, CD31, CK, and Vimentin were found to be positive, while CD34 was negative. Apatinib was initially administered 250 mg daily doses and after 1 month was increased to 500 mg daily.
He showed noticeable symptomatic improvements and positive imaging changes in the first month of treatment. However, the disease progressed in the following month, despite the increased apatinib dose.
Apatinib is possibly a new treatment for P-EHE. However, further clinical trials are necessary to confirm an effective dose and the efficacy and safety of apatinib in P-EHE treatment.
肺上皮样血管内皮瘤（P-EHE）是一种罕见肿瘤，尚无既定的标准治疗方法。据报道，部分P-EHE患者存在血管内皮生长因子受体2（VEGFR-2）过表达。阿帕替尼是一种专门靶向VEGFR-2的新型小分子酪氨酸激酶抑制剂，在一些晚期肿瘤中具有治疗作用。然而，其在P-EHE病例中的疗效尚未见报道。
在此，我们报告一名44岁男性，反复咯血约9年。
住院后进行了相关检查。该疾病随后被诊断为P-EHE。
患者接受了肺叶切除术，但随后出现多处转移。在肿瘤内，发现CD31、细胞角蛋白（CK）和波形蛋白呈阳性，而CD34呈阴性。阿帕替尼最初每日剂量为250毫克，1个月后增至每日500毫克。
在治疗的第一个月，他的症状有明显改善，影像学检查也出现积极变化。然而，尽管阿帕替尼剂量增加，但在下个月病情仍进展。
阿帕替尼可能是P-EHE的一种新的治疗方法。然而，需要进一步的临床试验来确定有效剂量以及阿帕替尼在P-EHE治疗中的疗效和安全性。
